BioRender 아이콘

Neuroblastoma (SH-SY5Y, differentiated 2)

Neuroblastoma (SH-SY5Y, differentiated 2) - Editable icon of Neuroblastoma (SH-SY5Y, differentiated 2)
[{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6991/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6991/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6990/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6990/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698f/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698f/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698e/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698e/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698d/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698d/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698c/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698c/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698b/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698b/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698a/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698a/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6989/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6989/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6988/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6988/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6987/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6987/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6986/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6986/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6985/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6985/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6984/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6984/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6983/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6983/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6982/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6982/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6981/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6981/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6980/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6980/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697f/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697f/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697e/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697e/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697d/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697d/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697c/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697c/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697b/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697b/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697a/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697a/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6979/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6979/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6978/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6978/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6977/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6977/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6976/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6976/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6975/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6975/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6974/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6974/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6973/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6973/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6972/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6972/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6971/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6971/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6970/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6970/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696f/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696f/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696e/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696e/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696d/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696d/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696c/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696c/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696b/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696b/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696a/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696a/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6969/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6969/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6968/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6968/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6967/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6967/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6966/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6966/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6965/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6965/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6964/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6964/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6963/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6963/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6962/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6962/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6961/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6961/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6960/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6960/630635d07c75bb00281a68f9.png"}]
이 아이콘 사용하기 – 무료
가입 시 신용카드가 필요하지 않습니다.

이 아이콘은 BioRender에서 자유롭게 편집할 수 있습니다

  • 텍스트, 도형 및 기타 아이콘 추가
  • 5만 개 이상의 과학적으로 정확한 아이콘을 검색하세요
  • 모든 아이콘, 선, 라벨의 색상과 배치를 자유롭게 변경하세요
  • 어떤 용도로든 내보내거나 공유하세요
Scientist Avatars

이미 출판용 수준의 그림을 만들고 있는 400만 명 이상의 과학자들과 함께하세요

아이콘으로 몇 분 만에 완성된 그림을 만들어 보세요

  • 검색 50,000개 이상의 과학적으로 정확하고 동료 검토를 거친 아이콘 제공
  • 맞춤 설정 라벨, 도형, 추가 아이콘을 사용하여 모든 요소를 자유롭게 편집할 수 있습니다.
  • 내보내기 또는 공동 작업자와 그림 공유하기
    ‍

찾으시는 아이콘이 아닌가요? 더 많은 아이콘을 확인해 보세요.

30개 이상의 생명과학 분야에 걸친 50,000개 이상의 아이콘을 검색하세요.

search icon
arrow-right
neuroblastoma,SH-sy5y,SK-N-SH,parkinson,neurogenesis,differentiated,differentiation,n type,SH-sy5y
더 보기

동의어를 검색하거나 가입하여 앱에서 아이콘을 요청해 보세요.

이미지 유형

Neuroblastoma (SH-SY5Y, differentiated 2) icon JPEG

Neuroblastoma (SH-SY5Y, differentiated 2) icon PNG

Neuroblastoma (SH-SY5Y, differentiated 2) icon SVG

Neuroblastoma (SH-SY5Y, differentiated 2) icon GIF

BioRender 아이콘 FAQ

How are scientists using the Neuroblastoma (SH-SY5Y, differentiated 2) icon in their work?

BioRender users often use the Neuroblastoma (SH-SY5Y, differentiated 2) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

이 아이콘을 BioRender 그림이나 과학 일러스트레이션에 사용할 수 있나요?

Yes, the Neuroblastoma (SH-SY5Y, differentiated 2) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Neuroblastoma (SH-SY5Y, differentiated 2) icon customizable in BioRender?

Most icons in BioRender, including the Neuroblastoma (SH-SY5Y, differentiated 2) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Neuroblastoma (SH-SY5Y, differentiated 2) icon for publication or presentations?

Yes, figures containing the Neuroblastoma (SH-SY5Y, differentiated 2) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Neuroblastoma (SH-SY5Y, differentiated 2) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Neuroblastoma (SH-SY5Y, differentiated 2) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

BioRender란 무엇인가요?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Neuroblastoma (SH-SY5Y, differentiated 2) icon along with our library of more than 30,000 life science icons.

BioRender에서 이 아이콘 사용하기

지금 바로 전문가 수준의 과학 피규어를 만들어 보세요
antibody elements3D Phospholipid illustration

과학 콘텐츠를 찾고 계신가요?

동료 검토를 거쳐 사용하기 쉽고 무료로 제공되는 5만 개 이상의 아이콘과 템플릿을 살펴보세요.

지금 바로 찾아보세요
x icon